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Abstract
Genes and pathways that allow cells to cope with oncogene-induced stress represent selec-
tive cancer therapeutic targets that remain largely undiscovered. In this study, we identify a
RhoJ signaling pathway that is a selective therapeutic target for BRAF mutant cells. RhoJ
deletion in BRAF mutant melanocytes modulates the expression of the pro-apoptotic protein
BAD as well as genes involved in cellular metabolism, impairing nevus formation, cellular
transformation, and metastasis. Short-term treatment of nascent melanoma tumors with
PAK inhibitors that block RhoJ signaling halts the growth of BRAF mutant melanoma tumors
in vivo and induces apoptosis in melanoma cells in vitro via a BAD-dependent mechanism.
As up to 50% of BRAF mutant human melanomas express high levels of RhoJ, these stud-
ies nominate the RhoJ-BAD signaling network as a therapeutic vulnerability for fledgling
BRAF mutant human tumors.
Author summary
BRAFV600E is the most common mutation in human melanomas, and kinase inhibitors
that block BRAFV600E signaling can rapidly induce tumor regression but only modestly
improve melanoma long-term survival. In this study, we identify a novel therapeutic vul-
nerability for BRAF mutant melanoma tumors. Targeting RhoJ signaling with existing
PAK inhibitors was more efficient at blocking the progression of BRAF mutant tumors in
vivowhen compared to kinase inhibitors currently used to treat melanoma. Approxi-
mately half of all human BRAF mutant melanoma tumors express high levels of RhoJ,
identifying the RhoJ-BAD pathway as a novel target for melanoma.
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Introduction
Oncogenes regulate cellular homeostasis in normal cells, and when mutated induce secondary
physiological changes that stress cellular capacity for survival [1, 2]. Paradoxically, oncogenes
drive the uncontrolled growth of tumor cells [3] and represent some of the most effective can-
cer therapeutic targets [4]. Unfortunately, inhibiting oncogene activity induces only short-
lived tumor regression [5], eventually resulting in the regrowth of tumors that activate growth
by other mechanisms [6–8]. Recent studies have sought to define pathways that allow tumor
cells to cope with oncogene-induced stress [9]. Cancer cells are known to alter conventional
signaling paradigms to skirt apoptotic stimuli [10]. In addition to avoiding apoptosis, tumor
cells rewire metabolism to further facilitate growth [11]. An emerging approach to treat cancer
is to identify non-mutated gene products critical for cancer cell and not normal cell survival
and develop novel therapeutics to target these gene products [12]. These “non-oncogene”
dependencies have proven effective drug targets for breast cancer and could potentially be
used in other cancers such as melanoma [13].
The BRAF oncogene is the most commonly mutated gene in human cutaneous melanomas
[14], and this oncogene also drives tumor cell proliferation [15]. BRAF mutations are not ex-
clusive to tumors as they are also seen in common human nevi [16] that spontaneously arrest
[2], and little is understood about what pathways allow BRAF mutant cells to proliferate to
form nevi. Activating BRAF mutations and the loss of the tumor suppressor PTEN are events
with a significant co-occurrence in melanoma [17]. These mutations result in the activation of
MAPK and AKT signaling networks that accelerate melanoma development by promoting cell
survival [18]. While MAPK and AKT signaling play an important role in melanoma progres-
sion, it is currently not clear what other pathways suppress oncogene-induced stress in BRAF
mutant cells to allow them to proliferate.
RNAi approaches have been used to uncover selective tumor dependencies and identify
novel therapeutic targets [19]. We previously used a genome-wide RNAi approach to identify
RhoJ, a Cdc42 family GTPase, as a gene that allows melanoma cells to resist DNA damage
stress in vitro [20]. RhoJ activates group I p21-activating kinases (PAK) in melanoma cells and
PAK inhibitors can sensitize melanoma cells to DNA damage [20, 21]. In addition to modulat-
ing DNA damage stress, RhoJ modulates actin cytoskeletal dynamics in melanoma cells [21],
and can regulate tumor angiogenesis in lung cancer xenografts [22]. Intriguingly, while RhoJ
modulates multiple pathways that may be involved in melanoma growth, it is not mutated in
melanoma tumors, suggesting that it may represent a “non-oncogene” dependence in tumor
cells. In this study, we utilize physiologically-relevant in vivo systems to examine the role that
RhoJ and its downstream targets PAK-BAD play in nevus formation and cellular transforma-
tion. We reveal that RhoJ modulates the growth properties and apoptotic threshold of BRAF
mutant melanocytes, accelerating both the formation of nevi and the growth and metastasis of
melanoma tumors. Surprisingly, treatment of mice with PAK inhibitors before tumors devel-
oped or during the early phases of tumor growth inhibits tumor growth and metastasis, nomi-
nating PAK inhibitors as a novel treatment for early-stage cutaneous melanomas.
Results
RhoJ regulates melanoma progression
To evaluate the role of RhoJ in melanoma development, constitutive RhoJ knockout (KO)
mice were crossed with a previously described autochthonous mouse model of melanoma that
carries a Tyr:CreERT2 allele, a BrafCA allele, and one or two copies of a Ptenlox4-5 allele [18] (S1A
Fig). Initial studies validated that RhoJ knockout mice lacked RhoJ expression (S1B Fig).
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RhoJ deletion significantly inhibited the growth of melanoma tumors that expressed either no
PTEN (p<0.0001, Log-rank; Fig 1A) or had one functional copy of PTEN (p<0.0001, Log-
rank; Fig 1B), suggesting that RhoJ drives tumor growth by amplifying BRAF and not AKT sig-
naling. Melanoma tumors from RhoJ KO mice metastasized to the lung at a lower rate as com-
pared to RhoJ wild type (WT) mice (p = 0.003, Student’s t-test; Fig 1C, S1C Fig), suggesting
that RhoJ regulates tumor progression, metastasis, or both. While the effects of RhoJ deletion
on lung metastasis was dramatic, it was difficult to examine whether this phenotype was a con-
sequence of a direct effect of RhoJ on lung metastasis or simply a consequence of the fact that
Fig 1. RhoJ regulates melanoma tumor development. (A) Loss of RhoJ prolongs survival of BRAFV600E and PTEN null
tumors. Kaplan-Meier survival analysis of 4-OHT treated BrafCA/+; Ptenfl/fl; Tyr::CreERT2; RhoJ+/+ (n = 12) and BrafCA/+;
Ptenfl/fl;Tyr::CreERT2; RhoJ-/- (n = 12) mice. Log-rank test demonstrates significant difference between BrafCA/+; Ptenfl/fl;Tyr::
CreERT2; RhoJ+/+ and BrafCA/+; Ptenfl/fl;Tyr::CreERT2; RhoJ-/- (p<0.0001). (B) RhoJ deletion prolongs the survival of mice
carrying BRAFV600E and PTEN haploinsufficient tumors. Kaplan-Meier survival curves of 4-OHT treated BrafCA/+; Ptenfl/+;
Tyr::CreERT2; RhoJ+/+ (n = 19), and BrafCA/+; Ptenfl/+; Tyr::CreERT2; RhoJ-/- (n = 13) mice. Log-rank test demonstrates
significant difference between BrafCA/+; Ptenfl/+; Tyr::CreERT2; RhoJ+/+ and BrafCA/+; Ptenfl/+; Tyr::CreERT2; RhoJ-/-
(p<0.0001). (C) RhoJ deletion reduces lung metastasis. Lung metastases were compared in aged-matched (P30) mice
using a dissection microscope (**p = 0.003, n = 8, Student’s t test). Error bars represent standard error of mean (SEM). (D)
RhoJ deletion inhibits melanoma development. The amount of pigment present on the paws at day 17 was analyzed with
ImageJ (*p = 0.04, n = 5, T-test). Error bars represent SEM. (E) RhoJ deletion delays melanoma progression. Paws of
4-OHT treated mice were imaged at 10, 17, and 24 days post birth.
https://doi.org/10.1371/journal.pgen.1006913.g001
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RhoJ knockout mice had a lower tumor burden than RhoJ wild type mice at p30 (Fig 1C, S1C
Fig). To determine whether RhoJ regulates tumor progression, tumors were induced on the
paws of experimental mice and the kinetics of tumor growth was measured. There was a signif-
icant delay in tumor progression in RhoJ KO mice as compared to RhoJ WT mice. RhoJ KO
mice developed early stage tumors (as measured by pigmented area) a week later than RhoJ
WT tumors (Fig 1D and 1E, S1D Fig), indicating that RhoJ promotes the growth of developing
melanoma tumors. When the paws of RhoJ KO mice were examined at a later timepoint
(P33), we observed that the paws of the animals appeared similar to what was observed in
RhoJ WT mice at p24 (S1E Fig), suggesting that RhoJ most likely affects either the initiation or
progression of tumors and that RhoJ knockout mice likely have similar numbers of paw mela-
nocytes as RhoJ wild type mice.
RhoJ modulates signaling pathways that control melanocyte
differentiation and survival
In order to better understand how RhoJ promotes tumor growth, the whole genome expres-
sion profiles of BrafV600E;Ptenfl/+;RhoJ+/+ tumors and BrafV600E;Ptenfl/+;RhoJ-/- tumors were
examined (Fig 2A, S2A Fig, complete list in S1 Dataset). Transcriptomics analysis revealed that
RhoJ modulates the expression of pigment genes such as premelanosome protein (Pmel17)
and Oca2 melanosomal transmembrane protein (Oca2) (Fig 2A). As a preliminary validation
of the pathways identified in our transcriptomics experiments, we sought to determine
whether RhoJ deletion affects melanogenesis. Initial observations revealed that RhoJ KO mice
exhibit a greater number of white hairs as compared to RhoJ WT mice (Fig 2B and 2C, S2B
Fig), indicating that RhoJ modulates either postnatal melanogenesis or melanocyte develop-
ment. Immunofluorescence studies revealed that RhoJ KO mice contained fewer melanocytes
that express Pmel17 (Fig 2D and 2E) yet have similar if not higher numbers of DCT-positive
melanocyte stem cells within the hair follicle (S2C and S2D Fig) when compared to RhoJ WT
mice. These results suggest that RhoJ modulates pigmentation by either causing a developmen-
tal melanocyte defect or by affecting melanocyte differentiation.
Interestingly, pathway enrichment analysis revealed that RhoJ deletion in mouse tumors
modulated pathways that have previously been shown to be regulated by BRAF, such as cellu-
lar bioenergetics (oxidative phosphorylation) [23], RAF and PI3 kinase signaling pathways
[24], UVB-induced MAPK signaling pathways [25], and p53 signaling pathways [20] (Fig 2F).
Notably cytokines, immune regulators, and angiogenesis regulators were not identified in our
bioinformatics analysis, suggesting that RhoJ regulates melanocyte growth in a cell autono-
mous manner. FoxC2, a gene that regulates the expression of multiple mitochondrial genes
[26], was up-regulated in RhoJ KO tumors as compared to RhoJ wild type tumors as demon-
strated by both RNA-seq results (Fig 2A) and by western blotting (Fig 2G). BRAF mutant cells
are known to suppress AKT and BAD signaling to promote their growth in vivo [27]. Intrigu-
ingly, we observed that the expression of the proapoptotic protein BAD was elevated in RhoJ
KO tumors (Fig 2H), consistent with the hypothesis that RhoJ downregulates BAD signaling.
Similarly, other apoptosis genes were also modulated by RhoJ (see S1 Dataset). Taken together,
these observations suggest that RhoJ modulates the growth of tumors by altering the metabo-
lism and apoptotic threshold of BRAF mutant melanocytes (S2E Fig).
RhoJ regulates the development of melanocytic nevi via a cell
autonomous mechanism
Our preliminary studies made the novel observation that RhoJ modulates melanocyte differen-
tiation (Fig 2B). Previously published studies determined that RhoJ is expressed in endothelial
RhoJ signaling promotes the growth of BRAF mutant melanomas
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cells in developing retinas [28], and RhoJ knockout mice exhibit delayed radial growth of the
retinal vasculature without other discernible angiogenesis phenotypes [29]. Our transcrip-
tomics analysis did not identify angiogenesis genes as a class that is modulated in RhoJ knock-
out tumors (Fig 2F), in contrast to previous studies that identified RhoJ as critical regulator of
angiogenesis in xenograft models [22]. Analysis of the vasculature from RhoJ KO melanomas
revealed no difference in the number of blood vessels per unit area in comparison to RhoJ WT
melanomas (Fig 3A and 3B, S3A Fig), indicating that RhoJ deletion does not significantly affect
tumor angiogenesis in our autochthonous mouse model. To further analyze the effects of RhoJ
on melanocytes, RhoJ KO mice were crossed with a nevi mouse model that carries a Tyr:
Fig 2. RhoJ modulates various signaling pathways to promote tumor growth. (A) Heat map plot of 50 modulated genes upon loss of RhoJ. Hierarchical
clustering of RNA-seq normalized read counts ranging from less frequently expressed (dark blue) to overexpressed (dark red) genes. (B) RhoJ KO mice
have a greater number of white hairs than RhoJ WT mice. Images of 8-month old mice show that loss of RhoJ induces accumulation of white hairs. (C) The
number of white hairs over an area of 1 in2 were counted and quantified using ImageJ (**p = 0.002, Student’s t-test). Error bars indicate SEM. (D) Loss of
RhoJ results in fewer PMEL17+ follicular melanocyte stem cells. Double labeling for the melanosome protein PMEL17 (red) in hair follicle melanocyte stem
cells (KIT+, green) at telogen demonstrates a noticeable reduction in the intensity and extent of PMEL expression in RhoJ KO mice. White dashed line
indicates the extent of the hair follicle. Scale bars: 10μm (E) Quantification of the immunolabeling described in D demonstrates a statistically significant
difference between RhoJ WT and RhoJ KO hairs (*p = 0.03, Student’s t test). Error bars indicate standard deviation of the mean. (F) RhoJ regulates
oxidative phosphorylation, melanocyte differentiation, and MAP kinase signaling. Based on the differentially expressed genes between melanoma tumors
from RhoJWT and RhoJKO mice, Ingenuity Pathway Analysis (IPA) generated an enrichment of canonical pathways regulated by RhoJ based on the
literature (pathways potentially regulated by BRAF are highlighted in red). Bars indicate the negative logarithm of the enrichment p-value. The orange dotted
line indicated the statistical threshold (p<0.05) for the enrichment canonical pathways. The orange squares indicate the ratio (value of molecules in a given
pathway that meet the cutoff criteria, divided by total number of molecules that make up that pathway) for each canonical pathway. (G) FoxC2 is up regulated
in mouse tumor samples. Melanoma tumor lysates were prepared for western blot and probed for the indicated Abs. Relative densitometry values are shown
below each blot. (H) BAD is up regulated in RhoJ KO mouse tumor samples. Melanoma tumor lysates were prepared for western blot and probed for the
indicated Abs. Relative densitometry values are shown below each blot.
https://doi.org/10.1371/journal.pgen.1006913.g002
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CreERT2 allele and a BrafCA allele [18]. Nevi were quantified microscopically with multiphoton
microscopy (MPM), a techniques that utilizes intrinsic fluorescent signals to generate a three-
dimensional image of nevi [30], at the second telogen (p50) after the hair was removed. Tyr:
CreERT2; BrafV600E; RhoJ-/- mice had reduced the number of microscopic nevi that could be
visualized from the skin surface as compared to Tyr:CreERT2; BrafV600E; RhoJ+/+ mice (Fig 3C
Fig 3. RhoJ regulates the formation of BRAF mutant nevi. (A) RhoJ deletion does not significantly affect
the angiogenesis of BRAF mutant autcthonous melanoma tumors. Tumor sections from age matched (post
natal day 30) BRAFV600E and PTEN null RhoJ KO or RhoJ WT mice were stained with smooth muscle actin
Ab followed by Alexa-488 secondary Ab to visualize blood vessels. Representative immunofluorescence
sections are shown. Scale bars: 100μm. (B) RhoJ KO and RhoJ WT melanomas have similar numbers of
vessels. The number of blood vessels in RhoJ WT and RhoJ KO per unit area (412μm x 412 μm) were
quantified. The number of blood vessels were not significantly different (p = 0.8, n = 6 (mice) and 3 areas per
tumor were counted). (C) RhoJ deletion inhibits nevus formation. MPM images were captured as described in
materials and methods from Tyr:CreERT2; BrafV600E; RhoJ+/+ and Tyr:CreERT2; BrafV600E; RhoJ-/-. Colored
lines indicate positions being displayed as xy (blue), xz (red) and yz (green) planes. Field of view is 636μm x
636μm Cyan: SHG of collagen; Green: fluorescence of keratin; Yellow and Red–fluorescence of melanin.
Nevus indicated by red arrows. Scale bars: 50μm. (D) Nevi were quantified within the upper 50μm from 3-D
skin reconstructions. Fewer microscopic nevi could be visualized from the skin surface in RhoJ KO skin as
compared to RhoJ wild type skin (p = 0.059, ANOVA, n = 10). (E) RhoJ deletion reduced the number of
macroscopic nevi visualized from the skin surface. Skin samples were fixed in 10% formalin for 36 hours and
dehydrated in a series of increasing alcohol concentrations, and nevi were visualized by a dissecting
microscope. Red arrows indicate pigmentation that could be visualized on the skin surface. (F) Macroscopic
nevi were quantified on skin samples that measured 25mm2. RhoJ KO samples contained fewer nevi
(p = 0.07, Student’s t-test, n = 4).
https://doi.org/10.1371/journal.pgen.1006913.g003
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and 3D, S3B Fig, S1 Video, S2 Video), a result that neared statistical significance (p = 0.059).
Similarly, less nevi were visualized macroscopically in RhoJ knockout mice as compared to
RhoJ wild type mice as visualized by a dissecting microscope (p = 0.07, Fig 3E and 3F, S3C
Fig). Our observations indicate that although RhoJ is a global KO, its deletion has no detectable
effect on the angiogenesis of autochthonous melanomas (S2C Fig). RhoJ deletion does affect
the growth of melanoma tumors, the formation of nevi, and has subtle effects on melanocyte
differentiation or development (S2D Fig). Taken together, these findings indicate that RhoJ
specifically modulates the growth and survival of melanocytes.
RhoJ is activated in a specific subset of melanoma tumors
Although RhoJ is highly expressed in the heart and to a lesser extent in the liver [31], its expres-
sion in cutaneous melanoma has not been extensively analyzed. We examined the expression
of RhoJ in a panel of human melanoma cell lines (Fig 4A) and determined that RhoJ expres-
sion levels varied widely in BRAFV600E and BRAFWT cells lines. Additional studies sought to
determine whether RhoJ signaling was activated in melanoma cells that express high levels of
Fig 4. RhoJ signals through PAK1 and is expressed in a subpopulation of Braf mutant human tumors. (A)
RhoJ is expressed in melanoma cell lines containing BRAFV600E mts. Lysates from various melanoma cell lines
containing WT BRAF or BRAFV600E mt were prepared and immunoblotted with the indicated Abs. BRAF and
PTEN status are indicated below each cell line. (B) RhoJ is activated in melanoma cells. Melanoma cell lysates
were analyzed in their initial state (“prior to unloading” lane) or after exchange and reloading with either GDP or
GTPγS. Protein lysates were then incubated with PAK-PBD Agarose beads and precipitated. Precipitated lysates
were subjected to immunoblotting using the indicated Abs. (C) RhoJ is expressed higher in stage III melanoma
tumors. Tumors were scored for RhoJ expression and quantified using standard H-score criteria (**p<0.001).
Stage IV tumors are a mixture of primary tumors and metastatic tumors. (D) RhoJ expression is higher in
BRAFV600E melanoma clinical specimens. TCGA SKCM RNA-seq data for RhoJ expression was compared
between BRAFWT (n = 168) and BRAFV600E (n = 130) melanoma specimens (*p = 0.02, Student’s t-test). (E)
BRAFV600E and RhoJ status among AJCC stage III and stage IV melanoma tumors. Tissue microarrays were
stained with an anti-BRAF mutant specific anti-S100, and an anti-RhoJ Abs as indicated. The percentage of
tumors that stained with S100 (positive control) Ab and also stained with RhoJ and/or the mutant BRAF Ab was
calculated.
https://doi.org/10.1371/journal.pgen.1006913.g004
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RhoJ. Our previously published studies showed that RhoJ regulates PAK activity in human
melanoma cell lines [20, 21]. Group I PAK kinases contain a p21-binding domain (PBD)
where small GTPases, like Cdc42, RhoJ, and Rac, can bind when they are in their GTP-bound-
active state [31]. We utilized a Cdc42-PAK functional assay to better evaluate the activation of
this family of GTPases in melanoma and determined that RhoJ, Cdc42, and Rac1/2/3 interact
with PAK in melanoma cells when they are GTP-bound but not when they are loaded with
GDP (Fig 4B). Interestingly, we observed that RhoJ and Cdc42 bind to PAK conjugated aga-
rose beads even when they are not loaded with GTP, suggesting that RhoJ and Cdc42 but not
Rac1 are intrinsically activated in RhoJ highly expressing cells (Fig 4B, “prior to unloading”
lane).
To verify that RhoJ plays a role in the growth of human melanomas, we optimized a RHOJ
Ab for immunohistochemistry (S4A Fig) and examined the expression of RHOJ in AJCC stage
III and stage IV melanoma tumors using two well-annotated melanoma tissue FFPE microar-
rays [32]. Stage III melanoma tumors expressed significantly higher levels of RHOJ than stage
IV melanoma tumors (Fig 4C, S4B Fig). RhoJ is also expressed in some stage II lesions (S4C
Fig), but large-scale examination of these lesions was limited by the number of that were avail-
able to test (these samples are often small in size and not included in most tissue microarrays).
Integration of the Cancer Genome Atlas (TCGA) melanoma RNA-sequencing and exome-
sequencing datasets confirmed a higher expression of RHOJ in BRAFV600E as compared to
BRAFWT melanoma tissues (Fig 4D). Moreover, 27% of all tumors examined in a human mela-
noma tissue microarray had both the BRAFV600E mutation and expressed high levels of RHOJ
(Fig 4E). Taken together, these studies indicate that RHOJ is expressed in about half of stage
III and stage IV melanoma tumors harboring BRAFV600E mutation.
PAK inhibitors selectively blocks the growth of RhoJ expressing
melanomas by suppressing BAD phosphorylation
Our initial studies demonstrated that RhoJ deletion slows the initiation and progression of
BRAF mutant melanoma tumors in vivo (Figs 1 and 3). To determine whether blocking RhoJ
signaling would be an effective method to inhibit the growth of melanoma tumors, we first
examined whether blocking RhoJ signaling pharmacologically was sufficient to induce apopto-
sis in vitro. Melanoma cell lines were treated with a Group I selective PAK inhibitor, FRAX597
[33]. FRAX597 induced apoptosis in BRAF mutant cell lines that expressed high levels of RhoJ
(WM3248 and WM983B), but not in BRAF wild type cell lines that expressed less RhoJ
(WM1366, Fig 5A). Moreover, FRAX597 induced low levels of apoptosis in cells where RhoJ
was undetectable, independently of the BRAF mutation status (Fig 5B). Previously published
studies have defined doses of Vemurafenib and Trametenib that can induce apoptosis in a
majority of treated cells in vitro after 72 hours [34]. Melanoma cell lines underwent apoptosis
when they were treated with Vemurafenib for 72 hours (S5A Fig), consistent with work pub-
lished by others [34]. FRAX597 induced more apoptosis than Vemurafenib and Trametenib
after 24 hours in cell lines that expressed detectable levels of RhoJ (Fig 5A). Interestingly,
increasing concentrations of FRAX597 inhibits the phosphorylation of ERK in BRAF mutant
cell lines while it has less of an effect on an NRAS mutant cell line (S5B Fig), which suggests
that RhoJ signaling may impact the MAP kinase pathway downstream of BRAF. In addition,
we observed that PAK inhibition in NRAS mutant cell line WM1366 does induce apoptosis,
but requires higher doses of drug (S5B Fig). Moreover, Pak inhibitors and BRAF inhibitors did
not synergistically kill melanoma cells (S5C Fig), suggesting that the effect of PAK inhibitors
on MAPK signaling may not be responsible for the observed apoptosis effect. PAK is known to
inhibit apoptosis by inducing the phosphorylation of BAD at serine 136, which inhibits the
RhoJ signaling promotes the growth of BRAF mutant melanomas
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Fig 5. PAK inhibition induces apoptosis via BAD and blocks the progression of BRAF mutant melanomas. (A) FRAX597 inhibits
PAK1 activation and induces apoptosis in BRAFV600E melanoma cell lines. Apoptosis was quantified with annexin-V labeling and flow
cytometry. (B) FRAX597 does not induce apoptosis in cell lines that do not express detectable RhoJ. Flow cytometry analysis of melanoma
cell lines treated with vehicle, vemurafenib (5μM), FRAX597 (1μM), or trametinib (0.1μM). (C) PAK inhibition decreases the phosphorylation
of BADSer 136. Melanoma cell line WM3248 harboring the BRAFV600E mutation was treated with an increasing concentration of FRAX597
(0μM, 0.2μM, 0.5μM, 1μM, 2.5μM, 5μM) and immunoblotted with the indicated antibodies. (D) Over expression of pcDNA3 BADS136E
RhoJ signaling promotes the growth of BRAF mutant melanomas
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ability of BAD to suppress the function of the anti-apoptotic protein BCL2 [35]. FRAX597
effectively inhibited the accumulation of BAD phosphorylated at Ser136 in a dose dependent
manner (Fig 5C). Overexpression of a BADS136E phosphomimetic [36] protected cells from
PAK-induced apoptosis (Fig 5D), indicating that PAK inhibitors induce apoptosis by blocking
BAD phosphorylation.
To determine whether PAK inhibition could block the growth of early stage melanoma
tumors, tumors were induced in adult mice as previously described [18] and treated with
FRAX597 for six days either one week after tumors were induced or two weeks after tumor
induction when tumors are first visible. Mice treated with FRAX597 for a short period of six
days before tumors were visible significantly prolonged the survival of mice by 30 days (p<
0.0021, Log-rank; Fig 5E), consistent with a role for RhoJ and PAK1 in the growth of nascent
tumors. Treating mice with FRAX 597 for six days after tumors were first visible resulted in
fewer tumors in FRAX597 treated mice as compared to vehicle treated mice (Fig 5F and S5D
Fig) as measured by the pigmented area (Fig 5G). Taken together, these results identify PAK
inhibitors as agents that can block the progression of early stage, BRAF mutant, RhoJ express-
ing melanomas by modulating BAD signaling.
Discussion
Oncogene-induced senescence and apoptosis play an important role in inhibiting tumorigenesis
by maintaining homeostasis [2]. In order to bypass homeostasis, tumors acquire mutations in
oncogenes, such as BRAF, but also alter conventional signaling paradigms to facilitate growth.
In this study, we sought to identify signaling pathways that allow melanoma cells to survive
BRAFV600E induced oncogenic stress. We identify a novel role for the Cdc42 family member RhoJ
in resisting the effects of oncogene-induced stress. RhoJ deletion had mild effects on normal mela-
nocyte differentiation and development, resulting in the accumulation of an increased number of
grey hairs. RhoJ played an even more important role during the process of nevus formation and
most significantly affected tumor development and metastasis. In this study, we were unable to
examine whether RhoJ had an independent effect on tumor metastasis as we had no method to
compare the number of metastasis in mice that had the same tumor burden. Future studies will
address whether RhoJ has independent effects on tumor initiation and metastasis.
While previously published studies have defined a role for Cdc42 in regulating melanoma
cell movement [37], this study represents the first identification of a specific Cdc42 signaling
network that cooperates with BRAF to regulate melanocyte growth in vivo. The observation
that RhoJ is not mutated in melanoma but yet plays a more important role in the growth of
phosphomimetic rescued survival after FRAX597 treatment. Cells were transfected with Lipofectamine 3000 according to the
manufacturer’s instructions and treated with FRAX or DMSO. Apoptosis was measured with flow cytometry. (E) PAK inhibition prolongs
survival in BrafV600E PTEN null mice. Melanoma was induced in adult mice at P21, P22, and P23 with topical treatment of 4-OHT (25mg/mL)
as previously described (18). Vehicle or FRAX597 (100mg/kg P.O. Q.D.) was administered for six days between P28 and P33. Mice were
euthanized when the tumor burden exceeded the minimum restrictions as advised by veterinary technicians, and Kaplan-Meier survival
curves were generated for BrafCA/+; Ptenfl/fl; Tyr::CreERT2; RhoJ+/+ vehicle (n = 5) or FRAX597 (n = 5) treated animals. Log-rank test
demonstrates significant difference between the two groups (**p<0.002, Log-rank test). (F) PAK inhibition delays tumor formation. Mice
were treated with 4-OHT at P21, P22, and P23 on their backs to induce melanoma. Tumors were allowed to progress for 2 weeks prior to
drug treatment. Mice were either administered FRAX597 or Vehicle for six days. Mice were euthanized after six days of drug treatment and
images were taken with a dissecting microscope. Tumors were visible in vehicle treated mice (arrows) but smaller lesions were visible
FRAX597 treated mice (arrowheads). (G) Disruption of RhoJ-PAK signaling blocks the formation of nevi and the growth of melanoma. The
area of pigmented lesions (developing melanomas) from F was quantified (A.U. arbitrary units) and analyzed (*p = 0.04, n = 3, Student t-
test). Error bars indicate SEM. (H) RhoJ expression enables melanocytes to differentiate and migrate out of the hair follicle during the
process of nevogenesis and evolve into melanoma tumors. Perturbation of RhoJ-Pak signaling prevents melanocytes from differentiating
normally, which leads to loss of pigment in hair, impairment of melanocytes to migrate out of the hair to form nevi, and prevent
transformation into melanoma as efficiently.
https://doi.org/10.1371/journal.pgen.1006913.g005
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BRAF mutant cells ranging from nevi to tumors indicate that RhoJ is part of a normal signal-
ing pathway that is co-opted to speed tumor development (Fig 5H). Interestingly, blocking
RhoJ signaling had some effect on MAPK signaling, suggesting that RhoJ does influence the
MAPK pathway. Future studies will examine how RhoJ cooperates with other MAPK drivers,
such as NRAS, to promote tumor growth.
To better understand how RhoJ and PAK regulate tumor formation, we examined how
RhoJ deletion affected gene expression in transformed melanocytes. Transcriptomic studies
revealed that RhoJ knockout tumors had increased expression of genes involved in oxidative
phosphorylation and the transcription factor FoxC2, which controls the expression of meta-
bolic pathways. Deregulation of cellular energetics, a hallmark of cancer [38], has been postu-
lated to be a mechanism to avoid oncogene-induced stress in melanoma [39]. Previous studies
have also shown that biguanides such as metformin and phenformin, electron transport chain
complex I inhibitors, when combined with BRAF inhibitors induce tumor regression in
BRAFV600E/PTENfl/fl mouse model of melanoma [40]. The observation that RhoJ modulates
the expression of complex I components (S2E Fig) but does not affect tumor angiogenesis in
our model (Fig 3A) identifies RhoJ signaling as a novel regulator of metabolic adaptation in
BRAF mutant melanoma cells.
In addition to modulating the expression of oxidative phosphorylation genes, loss of RhoJ
also led to an upregulation of the pro-apoptotic gene BAD. PAK is known to activate BAD
phosphorylation, promoting BAD binding to 14-3-3τ instead of Bcl2, resulting in increased
survival [35]. Overexpression of a BAD phosphomimetic mutant protected cells from the
effects of a PAK inhibitor (Fig 5E), verifying that PAK inhibitors modulate cell survival by reg-
ulating BAD activity. We observed that RhoJ knockout tumors induced BAD expression,
while acute inhibition of PAK modulated BAD activity but not BAD levels. These results are
likely a consequence of chronic versus acute inhibition of RhoJ and PAK signaling, respec-
tively. Anoikis occurs when cells can no longer adhere to the extracellular matrix and undergo
apoptosis [41]. Migrating cancer cells leave the primary niche and avoid anoikis because they
express mutated oncogenes and other genes that block apoptosis induction [42]. Previous
studies have demonstrated that the BRAF oncogene protects melanoma cells from anoikis by
modulating BAD signaling [43]. Similarly, PAK activation, which is overexpressed in breast
cancer, is known to protect MCF10A cells from undergoing anoikis [44]. Taken together, our
studies identify RhoJ and PAK as critical regulators of both metabolic adaptation and apopto-
sis evasion, key events required to establish the tumorigenic platform.
To validate whether the RhoJ-PAK signaling network influenced the growth of BRAF
mutant tumors, we determined whether PAK inhibitors could block the growth of BRAF
mutant autochthonous mouse melanomas during early phases of development. The PAK
inhibitor FRAX597 inhibits the growth of nascent tumors in vivo after only six days of treat-
ment (Fig 5E) and induces apoptosis in vitro after 24 hours (Fig 5A) by blocking BAD phos-
phorylation (Fig 5C). While FRAX597 does have some effects on modulating MAP kinase
signaling, these agents do not synergize with Vemurafenib to kill melanoma cells suggesting
that these agents induce apoptosis by modulating BAD and not by modulating MAPK signal-
ing. Interestingly, FRAX597 has more dramatic effects on MAPK signaling in BRAF mutant
cells as compared to NRAS mutant cells, suggesting that these agents may also impact signaling
downstream of BRAF (S5B Fig). Future studies will examine the connections between RhoJ-
PAK signaling and MAPK signaling. Finally, administering FRAX597 after tumors were visible
also affected tumor growth (Fig 5G), suggesting that PAK and RhoJ modulate both the phases
of tumor initiation and tumor progression.
It is interesting to note that the results presented here are more dramatic than other
studies which demonstrated that the BRAF inhibitor PLX4720, the precursor derivative of
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Vemurafenib, only moderately inhibited tumor growth in vivowithout inducing tumor regres-
sion [45] or preventing relapse [27]. These results again suggest that FRAX597 inhibits tumor
growth by a mechanism other than altering MAPK signaling. Of note, while the MEK inhibitor
PD325901 can induce tumor regression and prolong survival in transgenic mouse models, this
requires long-term treatment (six weeks) [18]. Previous studies have documented that PAK1 is
amplified in BRAF wild type tumors [46] and identified PAK inhibitors as agents that can slow
the growth of melanoma xenografts [47] and synergize with BRAF inhibitors to kill melanoma
cells [48]. In contrast, the studies presented here define a role for RhoJ signaling in regulating
the growth of BRAF mutant melanocytes at all stages (Fig 5H), and result in the remarkable
observation that early, limited treatment with PAK inhibitors is effective in halting tumor
growth. Our tissue microarray studies determine that RhoJ is more highly expressed in stage
III disease as compared to stage IV disease, suggesting that RhoJ is likely a better therapeutic
target in early stage melanomas. Future studies will involve assembling tissue collections of
early stage melanomas to verify whether RhoJ is an ideal therapeutic target for early stage dis-
ease and determine whether RhoJ inhibition blocks both tumor growth and metastasis.
Materials and methods
Mice
RhoJ KO mice were generated as previously described [29]. Briefly, the ES cells used to gener-
ate RhoJ knockout mice were derived from C57Bl/6N-RhoJtm1a(KOMP)Wtsi and injected into
C57B6/J mice to generate chimeric mice. The melanoma prone mice have the genetic back-
ground C57BL/6.Cg- Braftm1Mmcm Ptentm1Hwu Tg(Tyr-cre/ERT2)13Bos/BosJ (BrafCA, Ptenlox4-5,
Tyr::CreERT2) that have been previously characterized [18]. Both mice strains were crossed to
generate BrafCA, Ptenlox4-5, Tyr::CreERT2, RhoJ-/- mice. The entire survival study utilized a total
of 19 males and 37 females. The pigmentation of the mouse paws were analyzed by measuring
the area of the pigmented region in the paws and normalizing to the entire paw using ImageJ
software. The quantification of the paws includes all the paws shown in the figures and sup-
porting figures.
Multiphoton microscopy of mouse skin
Tyr:CreERT2; BrafV600E; RhoJ+/+ and Tyr:CreERT2; BrafV600E; RhoJ-/- mice were shave depilated at
p50 (second telogen), euthanized, and immediately imaged ex-vivo (no labeling) with MPM to
capture the fluorescence signal from keratin and melanin and second harmonic generated
(SHG) signal from collagen using LSM 510 NLO Zeiss system. Fluorescence and second har-
monic generation was excited by femtosecond Titanium: Sapphire (Chameleon-Ultra, Coher-
ent) laser at 900 nm. Emission was detected at 390–465 nm for SHG channel (blue), and 500–
550 nm (green) and 565–650 (red) fluorescence channels. Each animal was imaged at 8 to 10
randomly chosen locations on depilated skin of the lower back. Stacks of optical sections of
636μm x 636μm at different depths ranging from 0 to 240 μm (5 μm steps) were obtained to
allow for 3-D volume reconstruction (LSM Image Browser, Carl Zeiss GMBH).
Activation of Tyr::CreERT2 transgene and treatment of mice with PAK
inhibitors
BrafCA, Ptenlox4-5, Tyr::CreERT2 mice were genotyped as previously described [18]. The Cre-spe-
cific primers are: forward 5’- GGTGTCCAATTTACTGACCGTACA-3’ and reverse 5’- CGG
ATCCGCCGCATAACCAGTG -3’. Topical administration of 4-hydroxytamoxifen (4-OHT)
to the back skin on pups and adults was performed as previously described [18]. Paws of mice
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were also treated with 4-OHT at P2, P3, and P4. FRAX597 was administered to mice daily via
oral gavage daily at a dose of 100 mg/kg [33] and prepared in 60%:40% PEG-400:DI water.
Tumors in adult mice (P21) were induced for three days and allowed to progress for one week,
at which point mice began FRAX treatment for six days. The veterinary staff was blinded as to
the genotype of experimental animals utilized in the study, and monitored experimental ani-
mals on a daily basis. Animals were culled when tumor burden reached ethical limits and if the
animals displayed signs of ill health or distress as determined by the veterinary staff. All mouse
procedures were approved by UCI’s IACUC regulations and standards. As an additional con-
trol for background strain variability, all survival comparisons were made between littermates.
RNA sequencing
Total RNA from RhoJ WT 1–5 and RhoJ KO 1–5 was monitored for quality control using the
Agilent Bioanalyzer Nano RNA chip (Santa Clara, CA). Samples with a RIN number >8 were
used to construct libraries using the Illumina TruSeq RNA v2 kit. The input quantity for total
RNA was 1μg and mRNA was enriched using oligo dT magnetic beads. The enriched mRNA
was chemically fragmented for four minutes. First strand synthesis used random primers and
reverse transcriptase to make cDNA. After second strand synthesis the ds cDNA was cleaned
using AMPure XP beads (Beckman Coulter, Beverly, MA) and the cDNA was end repaired
and then the 3’ ends were adenylated. Illumina barcoded adapters were ligated on the ends
and the adapter-ligated fragments were enriched by nine cycles of PCR. The resulting libraries
were validated by qPCR and sized by Agilent Bioanalyzer DNA high sensitivity chip. The con-
centrations for the libraries were normalized and then multiplexed together. The concentra-
tion for clustering on the flow cell was 12.5pM. The multiplexed libraries were sequenced on
three lanes using paired end 100 cycles chemistry for the Illumina HiSeq 2500. The version of
HiSeq control software was HCS 2.2.38 with real time analysis software, RTA 1.18.61.
Immunohistochemistry, immunofluorescence and immunoblotting
RhoJ staining was optimized at 1:1000 using an Ab from Genetex (Irvine, CA). Slides were
developed with either a horse-radish peroxidase liquid 3,3’-diaminobenzidine chromogen sys-
tem (DAKO, Carpirteria, CA) or an alkaline phosphatase liquid permanent red chromogen
system (DAKO), according to the manufacture’s protocol. Fluorescence labeling was per-
formed using SMA (Abcam 1:100) PMEL, KIT, DCT, and DAPI as described [49]. The expres-
sion or phosphorylation of proteins was detected by western blotting using the following Abs:
RhoJ (Abnova 1:250), Cdc42, Rac1/2/3, RhoA, actin, BAD, phospho-BadSer138, and Vinculin
(all from cell signaling 1:1000).
Cdc42 activity assays
A Cdc42 activation assay was performed according the manufacturer’s protocol (Cell Biolabs,
San Diego, CA). Briefly, cell lysates expressing high RhoJ were unloaded of guanosine nucleo-
tides and either loaded with GDP or GTPγS. Agarose beads conjugated with the PAK1 PBD
domain pulled down Cdc42, Rac, or RhoJ only when GTP-bound. Lysates were then immuno-
blotted with indicated Abs.
Flow cytometric analyses for apoptosis
Approximately 1 × 106 melanoma cell treated with FRAX-597 were trypsinized and washed
with PBS, the single-cell suspensions were incubated with Alexa Fluor-Annexin V and propi-
dium iodide (PI) (V13245; Invitrogen) per the manufacturer’s protocol and were subjected to
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flow cytometric analysis. In all cases, cell debris was gated out based on forward scatter and
side scatter analysis. Data was analyzed using FlowJo (Ashland, OR). Cells not treated with
FRAX-597 were used to establish gating parameters. WM3248 cells were transfected with
BADS136E (3582 pcDNA3 BADS136E Addgene #8800), with Lipofectamine 3000 (Invitrogen)
according to the manufacturer’s protocol. On the day of transfection, 14μg of DNA from the
respective constructs were incubated with Plus Reagent in Opti-MEM to a volume of 350μL,
and then mixed with 43μL lipofectamine in 350μL Opti-MEM and incubated for 20 min at
room temperature. The DNA-Lipofectamine complexes were then added to each plate, and
the cells were incubated at 37˚C in a CO2 incubator. The media was replaced after 24hrs and
cells selected in G418.
Statistical analysis
The power and sample size calculations for the survival studies (Fig 1A and 1B) were based on
a simulation of 1000 datasets utilizing SAS v9.2. To calculate the power, the simulation under
the alternative hypothesis made the following assumptions: 1.) No censoring data for both
groups; 2.) The first event occurred on day 30 for the controls; 3.) The first event occurred on
day 40 for RhoJ-/-; 4.) Hazard ratios used were 1.5, 2, 4, 6; and 5.) Sample size of mice per
group was 15, 20, 25, 30, 40, and 50. To calculate the type I error (alpha) under the null hypoth-
esis the following assumptions were made: 1.) Data was not censored for both groups; 2.) The
first event occurred on day 30 for both groups; 3.) Hazard ratio is 1; and 4.) Sample size of the
mice per group was 15, 20, 25, 30, 40, and 50.
Continuous outcomes were summarized via mean and standard error and tests of unad-
justed means between groups were conducted using a two-sample t-test with unequal variances.
Mean RhoJ expression levels adjusting for stage, age and gender were estimated and compared
using multiple linear regression analysis. Residual diagnostics were performed in order to assess
the functional form of continuous covariates included in the model and to identify potentially
influential subjects. Estimated mean differences, corresponding Wald-based 95% confidence
intervals, and p-values corresponding to the test of no association in RhoJ levels were reported
for all model covariates. No deviations in model fit or influential observations were observed.
The TCGA analysis was performed as follows. The skin cutaneous melanoma (SKCM)
TCGA Exome-sequencing and RNA-sequencing datasets were downloaded June 2016. Single
nucleotide variants (SNVs) at the position 1799 of the BRAF gene (c.1799T>C) leading to a
non-synonymous alteration at the amino acid 600 of the BRAF protein were annotated as
BRAFV600E. Additional, RhoJ expression assessed by RNA-sequencing was normalized
using the z-score and the statistical difference on mean expression between BRAF wt and
BRAFV600E was assessed by the Student’s t-test.
Study approval
Mice were housed and maintained by the University Laboratory Animal Resources. All animal
experiments were approved by the University of California, Irvine’s Institutional Animal Care
and Use Committee. Melanoma tumor microarray tissues were collected and processed with
approval from the Providence Saint John’s Health Center and John Wayne Cancer Institute
joint Institutional Review Board and Western Institutional Review Board.
Supporting information
S1 Fig. RhoJ regulates melanoma tumor development. (A) Inducible melanoma mouse
model containing Braf mutation (mt), loss of Pten and RhoJ. Mice carrying BrafCA/+, Ptenfl/fl
and Tyr:CreERT2 alleles were crossed with constitutive RhoJ KO mice. Activation of CreERT2 by
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4-OHT leads to a BrafV600E mutation and Pten loss. (B) RhoJ is not expressed in Rhoj KO
mice. Formalin-fixed paraffin embedded mouse melanoma skin was bleached with 3% hydro-
gen peroxide (overnight) to remove melanin and analyzed for expression of RhoJ. (C) RhoJ
KO mice have reduced number of lung metastases. Representative lungs from aged-matched
mice (P30) were stained with H&E in BrafCA/+; Ptenfl/fl;Tyr::CreER; RhoJ+/+ (top panels) and
BrafCA/+; Ptenfl/fl;Tyr::CreER; RhoJ-/- (bottom panels) animals. Melanoma cells were identified
by their pigmentation characteristic. Scale bar is 200μm. (D) RhoJ deletion delays melanoma
development. Paws of 4-OHT treated mice were imaged at 10, 17, and 24 days post birth. The
mice depicted were utilized to generate the graphs shown in Fig 1D. (E) RhoJ KO paws eventu-
ally reach the same level of pigmentation as RhoJ WT paws. Paws of 4-OHT treated RhoJ KO
mice were imaged at P33.
(TIF)
S2 Fig. RhoJ modulates various signaling pathways to promote tumor growth. (A) Heat
map of 50 different modulated genes upon loss of RhoJ. Hierarchical clustering of RNA-seq
count reads ranging from less frequently expressed (dark blue) to overexpressed (dark red).
(B) RhoJ KO mice have a greater number of white hairs than RhoJ WT mice. Images of
8-month old mice show that loss of RhoJ induces accumulation of white hairs. (C) Melanocyte
stem cells reside in the hair germ of RhoJ KO hair follicles. Both RhoJ WT and RhoJ KO skins
exhibit telogen stage hair follicles that contain DCT+ (red) McSCs. White dashed line indicates
the extent of the hair follicle. Scale bars: 10μm. (D) Quantitative analysis of DCT+ cells that
reside in the hair follicle or RhoJ KO and RhoJ WT mice are represented as a box and whisker
box plot. The box plot is the 25-75th percentile and the whiskers are the min and the max. (E)
Bioenergetic genes, found throughout the electron transport chain, upregulated when RhoJ is
absent are shown. Note the number of genes that are present in complex I.
(TIF)
S3 Fig. RhoJ has a cell autonomous effect on melanocytes independent of angiogenesis. (A)
RhoJ expression does not affect the number blood vessels. Tumor sections from age matched
(post natal day 30) BRAFV600E and PTEN null mice were stained with smooth muscle actin fol-
lowed by Alexa-488 secondary antibody to visualize blood vessels. All stained sections are
shown (Field of view 412μm x412μm). Scale bars: 100μm. (B) RhoJ deletion inhibits nevus for-
mation. MPM images were captured as described in materials and methods from BRAFV600E;
RhoJ-/- mouse skin. Colored lines indicate positions being displayed as xy (blue), xz (red) and
yz (green) planes. Field of view is 636μm x 636μm Cyan: SHG of collagen; Green: fluorescence
of keratin; Yellow and Red–fluorescence of melanin. Nevus indicated by red arrows. Scale
bars: 50μm. (C) RhoJ deletion reduced the number of nevi that could be visualized on the skin
surface. Skin samples were fixed in 10% formalin for 36 hours and dehydrated in a series of
increasing alcohol concentrations and imaged using a dissecting microscope to visualize nevi
on the skin surface. Red arrows indicate a nevus.
(TIF)
S4 Fig. RhoJ is expressed in a subpopulation of Braf mutant human tumors. (A) Optimiza-
tion of RhoJ antibody for immunohistochemistry evaluation of AJCC stage III and IV TMAs.
Human melanoma tumors were stained with an optimized RhoJ Ab and developed with liquid
permanent red. Representative samples with the indicated H-score were determined by a der-
matopathologist. (B) Over 50% of human melanomas express RhoJ. Quantification of RhoJ
+ tumors were based on H-score. (C) Stage II melanomas express RhoJ. Stage II TMA were
obtained from US Biomax (ME481a) and developed with DAB.
(TIF)
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S5 Fig. Pak inhibition induces apoptosis via BAD and blocks the progression of BRAF
mutant melanomas. (A) Melanoma cells undergo apoptosis with a 72 hour treatment of
FRAX597, Vemurafenib, or Trametinib. All of the cells from WM3248 underwent apoptosis
when treated with FRAX597 by 72 hours and is not shown in the graph. (B) FRAX597 inhibits
Pak1 activation and induces apoptosis in BRAFV600E melanoma cell lines. Melanoma cell lines
harboring either BRAFV600E or BRAFWT were treated with increasing concentrations of
FRAX597 (0μM, 0.2 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM) and immunoblotted with the indicated
Abs to measure Pak1 activation (pMEKSer298) and apoptosis (cleaved PARP). (C) FRAX597
does not synergize with Vemurafenib. Cells were treated with either FRAX597, Vemurafenib,
or both and processed with FACS. (D) Pak inhibition delays tumor formation. Melanoma was
induced as described Fig 5F and administered with vehicle or FRAX597 via oral gavage. Skin
images were captured using a dissection scope.
(TIF)
S1 Dataset. List of genes regulated by RhoJ based on RNA-sequencing analysis. RNA sam-
ples were obtained from RhoJ wildtype (n = 5) and knockout (n = 5) mice and subjected to
RNA sequencing and analysis with Tuxedo Suite as previously described [50]. Briefly, the
RNA-sequencing reads were aligned to the mouse (Mus musculus; mm10) genome using
TopHat. Transcripts were assembled and compared with Cufflinks and Cuffdiff, respectively,
to find differentially expressed genes between the two groups. Apoptosis tab: List of apoptosis
genes regulated by RhoJ.
(XLSX)
S1 Video. RhoJ regulates the formation of BRAF mutant nevi. Stacks of optical sections of
636μmx636μm at different depths ranging from 0 to 240 μm (5 μm steps) were obtained to
allow for 3-D volume reconstruction (LSM Image Browser, Carl Zeiss GMBH). A representa-
tive 3-D volume reconstructed movie of Tyr:CreERT2; BrafV600E; RhoJ+/+ is shown. Cyan: SHG
of collagen; Green: fluorescence of keratin; Yellow and Red–fluorescence of melanin.
(AVI)
S2 Video. RhoJ regulates the formation of BRAF mutant nevi. Stacks of optical sections of
597 636μmx636μm at different depths ranging from 0 to 240 μm (5 μm steps) were obtained to
598 allow for 3-D volume reconstruction (LSM Image Browser, Carl Zeiss GMBH). A repre-
sentative 3-D volume reconstructed movie of Tyr:CreERT2; BrafV600E; RhoJ-/- is shown. Cyan:
SHG of collagen; Green: fluorescence of keratin; Yellow and Red–fluorescence of melanin.
(AVI)
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